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Abstract
Background:  TH1 immune response antagonism is a desirable approach to mitigate some
autoimmune and inflammatory reactions during the course of several diseases where IL-2 and IFN-
γ are two central players. Therefore, the neutralization of both cytokines could provide beneficial
effects in patients suffering from autoimmune or inflammatory illnesses.
Results: A chimeric antagonist that can antagonize the action of TH1 immunity mediators, IFN-γ
and IL-2, was designed, engineered, expressed in E. coli, purified and evaluated for its in vitro
biological activities. The TH1 antagonist molecule consists of the extracellular region for the human
IFNγ receptor chain 1 fused by a four-aminoacid linker peptide to human 60 N-terminal aminoacid
residues of IL-2. The corresponding gene fragments were isolated by RT-PCR and cloned in the
pTPV-1 vector. E. coli (W3110 strain) was transformed with this vector. The chimeric protein was
expressed at high level as inclusion bodies. The protein was partially purified by pelleting and
washing. It was then solubilized with strong denaturant and finally refolded by gel filtration. In vitro
biological activity of chimera was demonstrated by inhibition of IFN-γ-dependent HLA-DR
expression in Colo 205 cells, inhibition of IFN-γ antiproliferative effect on HEp-2 cells, and by a
bidirectional effect in assays for IL-2 T-cell dependent proliferation: agonism in the absence versus
inhibition in the presence of IL-2.
Conclusion: TH1 antagonist is a chimeric protein that inhibits the in vitro biological activities of
human IFN-γ, and is a partial agonist/antagonist of human IL-2. With these attributes, the chimera
has the potential to offer a new opportunity for the treatment of autoimmune and inflammatory
diseases.
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Background
Interferon gamma (IFN-γ), produced by activated T and
NK cells [1], macrophages and dendritic cells [2], has
important immunomodulatory and inflammatory
actions [3,4]. The activities of IFN-γ are initiated following
association of the cytokine with a membrane-bound
receptor (IFNGR) present on many cell types [5]. The
receptor comprises two subunits (IFNGR1 and IFNGR2).
IFNGR1 has an extracellular portion of 228 residues [6],
that also occurs in soluble form and can function as an
endogenous IFN-γ inhibitor [7]. Several pathological
effects have been ascribed to IFN-γ in animal models and
in humans. IFN-γ neutralization inhibits the lethal effect
of endotoxin in an animal model of septic shock [8], as
well as the rejection of tumor, skin, and heart allografts
[9,10]. IFN-γ-mediates pancreatic beta-cell death and the
subsequent development of immune-mediated diabetes
[11,12] and accelerates the development of lupus-like dis-
ease and nephritis in NZW × NZB- after treatment of F1
mice, whereas antibodies to IFN-γ can block or delay the
progression of the disease [13,14]. Additionally, adminis-
tration of IFN-γ can promote the development of reactive
gliosis in the central nervous system (CNS) of adult mice
[15] and aggravate the course of multiple sclerosis in
humans [16]. These observations suggest that IFN-γ antag-
onist may have therapeutic application in autoimmune
diseases, chronic inflammation, and allograft rejection.
Recently, an anti-IFNγ antibody (Fontolizumab) has been
demonstrated to be of a clinical benefit in patients suffer-
ing from Crohn's disease [17].
Interleukin 2 (IL-2) is a lymphokine synthesized and
secreted primarily by T-helper lymphocytes that have
been activated by stimulation with certain mitogens or by
interaction of the T-cell receptor complex with an antigen/
MHC complex on the surfaces of antigen-presenting cells
[18]. The biological activities of IL-2 are mediated through
its binding to a multisubunit cellular receptor. Although
three distinct transmembrane glycoprotein subunits con-
tribute to the formation of the "definitive" high affinity IL-
2 receptor, various combinations of receptor subunits are
known to occur [19,20]. Resting cells do not express high-
affinity IL-2R, but activation with antigen rapidly [21]
induces expression.
The main non-redundant activity of IL-2 consists in the
regulation of T-cell tolerance [22] and along with IFN-γ
and TNF-β, it is a defining product of the TH1 subset. Pro-
duction of IL-2 may contribute to the pathogenesis of
some diseases: overproduction of IL-2 has been seen in
patients with multiple sclerosis [23-25], systemic lupus
erythematosus relapses [26], myasthenia gravis [27] and
psoriasis [28]. However, recent studies indicate that fail-
ure of CD4 (+) CD25 (+) regulatory T cells to develop is
the underlying cause of autoimmunity in the absence of
IL-2 [22]. These observations indicating that both IFN-γ
and IL-2 can promote pathogenesis of inflammation,
prompted us to develop a chimeric protein TH1 antago-
nist that can simultaneously modulate the biological
activities of both cytokines.
Results and discussion
Construction and expression of TH1 antagonist
The poly-A mRNA for each nucleic acid to be cloned was
amplified from Jurkat and Raji cells expressing IL-2 and
high levels of IFNGR1, respectively. cDNAs for hu IL-2 N-
terminal fragment (coding for the first 60 aminoacid resi-
dues) and IFNGR1 subunit extracellular region (coding
for 228 amino acids) were isolated by RT-PCR amplifica-
tion of isolated poly-A mRNA. The cloning strategy
included amplification of each cDNA fragment using
primers with overlapping nucleotides to permit fusion of
the two bands in a later second round-PCR. The fragments
were joined in a second PCR using the 5' primer from IL-
2 fragment amplification and the 3' primer for IFNGR1
extracellular fragment first-round amplification.
These primers contain the sequences suited for Nco I and
Bam HI restriction enzyme cuts, compatible with respec-
tive restriction sites in the pTPV-1 expression vector, in
which the final fused cDNA was inserted. The resulting
vector contains a BamHI site just before the translational
stop codon and the cloned fragment is denoted pHu
(AnTH1). Figure 1 summarizes the strategy followed to
obtain the expression vector pHu (AnTH1).
Expression and purification of AnTH1
W3110 P3 E. coli cells were transformed with pHu
(AnTH1) plasmid incubated in 500 mL growth medium
yielded about 1 g of E. coli wet biomass, in which TH1
antagonist protein constituted about 30 % of the total
protein (Figure 2A). A small quantity of TH1 antagonist
was expressed at the start of the induction period, likely
related to the fact that pTrip is a strong promoter difficult
to be completely silenced. In the same figure, the lanes
corresponding to the negative control show a band much
fainter with the same migration rate as that of the recom-
binant molecule. This band was not observed after purifi-
cation steps and therefore probably represents a co-
migrating E. coli protein.
Since expression in E. coli culture resulted in accumulation
of the recombinant protein in insoluble "inclusion bod-
ies", purification of expressed chimera was performed by
washing the pellets using a low urea concentration, fol-
lowed by a high urea concentration for the extraction (sol-
ubilization) processes. Comparative studies showed that
8 mol/L urea solubilized approximately the 78% of
recombinant protein (see Table 1); lower concentrations
of urea were less efficient (Figure. 2B and 2C) and wereBMC Biotechnology 2006, 6:25 http://www.biomedcentral.com/1472-6750/6/25
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used for the washing steps. This approach achieves a good
performance; since in the washed pellet the insoluble
recombinant protein is retained while soluble E. coli pro-
teins are washed out, providing a high grade of purifica-
tion at the end of the process.
During the refolding process, realized by moving to a mild
denaturating agent and finally to a physiological buffer,
the reduced denatured protein recovers its active confor-
mation, as demonstrated by protein ligand blots, where
the active soluble chimera specifically bound radiolabed
hu recombinant IFN-γ (Figure 3), as well as by biological
Construction of the expression plasmid pHu (AnTH1) Figure 1
Construction of the expression plasmid pHu (AnTH1). The figure illustrates the process started from Poly-A mRNA 
purification from cell lines, followed by the RT-PCR of respective cDNA fragments. The amplified cDNA TH1 antagonist 
(AnTh1) contains in its extremes the sequences for NcoI and BamHI restriction enzymes suited for cloning in the pPTV-1 vec-
tor (left at the bottom of diagram). In the center is indicated the nucleotide sequence (ccatatgatg) coding for the linking pep-
tide. The final genetic construction is shown at the bottom right.
RT -PCR
IL-2 IFNGR1s
Nucleotides for: 
N-terminal IL-2-peptide Peptide-IFNGR1s
Second PCR 
cDNA AnTh1
Nco I              cccatatgatg Bam HI
Cells
poly A mRNA BMC Biotechnology 2006, 6:25 http://www.biomedcentral.com/1472-6750/6/25
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activity tests (see the next section). The main recombinant
product is a 33 kDa or 37 kDa protein in non-reduced or
reduced conditions, respectively, as recognized by anti-IL-
2 polyclonal antibody (Figure 4A). Shift in mobility of
TH1 antagonist between non-reducing and reduced
eletrophoretic conditions is in correspondence with what
has been reported for the soluble IFNGR [29] and for sev-
eral other receptors [30,31] and is consistent with a more
compact structure of folded protein. Polymeric and mon-
omeric forms were detected, probably as a consequence of
various alternative possibilities in the formation of
disulfide bonds among the nine sulphydryl groups of the
protein [32]. The anti-IL-2 polyclonal antibody strongly
recognized the rhu IL-2 in Western blots, while the chi-
mera was recognized less intensely, likely due to the small
IL-2 fragment represented in the recombinant antagonist
(see Figure 4B).
Mass spectrometric analysis
The tryptic peptides ESI-MS spectrum of TH1 antagonist
was obtained with a very good agreement between the
molecular masses of the predicted proteolytic fragments
and the experimental values. A summary of this compari-
son is shown in Table 2. Three tryptic peptides containing
Table 1: Balance of several processes of AnTH1 solubilization
Total protein (mg) % of solubilization
Process Step Exp #1 Exp #2 Exp #3 Exp #1 Exp #2 Exp #3
Supernatant 4 M urea wash 1015.2 92.3 246 NE NE NE
Pellet 4 M urea wash 1045.2 378 740 NE NE NE
Supernatant 8 M urea solubilization 905.8 264 589 86 69.8 79.5
Pellet 8 M urea solubilization 24 16.5 23 NE NE NE
% of solubilization: The amount of protien in inclusion bodies in 4 M urea pellet wash solubilized with 8 M urea and present in the supernatant of 8 
M urea.
(total protien (mg) supernatant 8 M urea/Total protein (mg) pellet 4 M urea) × 100.
NE: non evaluated.
E coli expression and urea extraction of recombinant chimeric protein Figure 2
E coli expression and urea extraction of recombinant chimeric protein. Panel A: Coomasie staining of 12.5% SDS-
PAGE in reduced conditions of samples from E coli expression. Lanes A, B, C: E coli strain negative control (empty vector), 0, 8 
and 18 hours of induction; Lanes D, E, F: E. coli strains containing the expression plasmid pHu (AnTH1) under induction condi-
tions: 0, 8, and 18 hours of induction. Panel B: Urea extraction. Coomasie staining of 12.5% SDS-PAGE under reducing condi-
tions. Lanes A, B, C, and D, pellets and lanes F, G, H, I, supernatants from extraction with 0, 2, 4 and 8 mol/L urea. Panel C: Lanes 
A, B, C, and D, pellets and lanes F, G, H, I, supernatants from extraction with 0, 5, 6 and 7 mol/L urea. Lanes E in panels B and C 
indicate the position of MW. The samples contain approximately the same amount of protein. The arrows indicate the position 
of AnTh1 recombinant protein
A  B     C  D E     F  G     H   I                            A   B       C   D E     F    G      H    I 
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kDa kDa
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50  50 
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MW     Clone (-)            Clone 28
0h     8h   18h     0h    8h  18h
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some of the sixty N-terminal amino acids of hu IL-2 (pep-
tides 1–3, Table 2) and the extracellular domain of
IFNGR1 were obtained (peptides 5–12, Table 2). The pep-
tide (56A-R66, peptide #4, Table 2) that links both pro-
teins was also detected in the ESI-MS spectrum,
confirming that a linker of four amino acids covalently
binds these two proteins. The results shown in Table 2,
account for 63 % sequence coverage, which is a satisfac-
tory result in the verification of primary structures of pro-
teins extracted from SDS-PAGE. The protein tryptic
spectrometric analysis showed the presence of fragments
corresponding to the IL-2 N-terminal and IFN-γ extracel-
lular regions confirming the presence of the components
of chimeric protein. In order to obtain a further confirma-
tion that this chimeric protein is present in the digested
band, the peptides corresponding to the four most intense
signals in the ESI-MS spectrum (data not shown) were
sequenced. Their ESI-MS/MS spectra were manually inter-
preted and partial sequences introduced into the PepSea
database search program. Peptide 1 (Table 2) is contained
in the N-terminal end of hu IL-2 whereas peptides 6, 11
and 12 (Table 2) belong to IFNGR1. These two polypep-
tides are fused into a single polypeptide chain that
migrates as a 33 kDa band as demonstrated by SDS-PAGE
(Figure 4A). The aminoacid (in one letter code) sequence
of the chimeric TH1 antagonist protein is the following:
(bold letters indicated the peptides identified by Mass
Spectrometric analysis, underlined is the linking peptide).
MAPTSSSTKKT11QLQLEHLLLDLQMILNGINNYK33NPKL
TRM40LTFK44F45YMPKK50ATELKH56LQCLAHMMSR66A6
7EMGTADLGPSSVPTPTNVTIESYNMNPIVYWEYQ101IM
PQVPVFTVEVK114NYGVKN120SEWIDACINISHHYCNIS
DHVGDPSNSWVR151VKARVGQKESAYAKS166EEFAVCR1
73DGKI177GPPK181LDIRKEEKQ190IMIDIFHPSVFVNGDE
Binding assay of rhu 125I-IFN-γ labeled to recombinant chi- meric protein using dot blot analysis Figure 3
Binding assay of rhu 125I-IFN-γ labeled to recom-
binant chimeric protein using dot blot analysis. 1 µl 
aliquots of the eluted fractions from the gel filtration chro-
matography (rows 1, 2, 3, 4, 5, 6) were applied to nitrocellu-
lose membrane strips. The strips were incubated with IFN-γ 
labeled with 125I (35 µCi/µg) in the absence (lane a) and in the 
presence (lane b) of 100 fold excess of human IFN-γ.
a                  b
1
2
3
4
5
6
Table 2: ESI-MS analysis of the tryptic peptides derived from the fused-protein
# Peptide sequencea) m/z exp. m/z theor. Zb) Abs. Errorc)
1 11T-K33
d) 908.81 908.83 3 0.02
2 40M-K44 639.34 639.35 1 0.01
3 45F-K50 685.33 685.33 1 0.00
4 56A-R66
f) 442.87 442.88 3 0.01
5 67A-K114 1781.52 1781.54 3 0.02
6 101Q-K114
d), e) 807.93 807.95 2 0.02
7 120N-R151
f) 921.14 921.17 4 0.03
8 166S-R173 506.23 506.23 2 0.00
9 177I-K181 511.31 511.28 1 0.03
10 190Q-R220
f) 1225.20 1225.23 3 0.03
11 221V-R227
d) 456.74 456.75 2 0.01
12 228M-K236
d) 535.24 535.25 2 0.01
a) The numbering in the sequences of peptides is according to the fused-protein sequence shown in the section Results and discussion.
b) Charge state of individual peptides.
c) Indicate the absolute mass difference between the theoretical and experimental molecular masses of the detected peptides.
d) Peptides sequenced by ESI-MS/MS.
e) Peptide originated by the non-specific cleavage of trypsin
f) Peptide containing free cysteine.BMC Biotechnology 2006, 6:25 http://www.biomedcentral.com/1472-6750/6/25
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QEVDYDPETTCYIR220V221YNVYVR227M228NGSEIQYK23
6ILTQKEDDCDEIQCQLAIPVSSLNSQYCVSAEGVLHVW
GVTTEKSKEVCITIFNSSIKG.
The analyzed results are compatible with the recombinant
chimeric antagonist protein comprising amino acids 1–60
from human IL-2 N-terminal followed by a peptide fol-
lowed by a peptide Ala-Hist-Met-Met  (underline in the
above aminoacid sequence) and the 228 aminoacids from
the human IFNGR1. This protein contains one cysteine
from IL-2 N-terminal and 8 cysteine residues from
IFNGR1 extracellular region. For comparison, the chi-
meric protein sequence with the known IL-2 and IFNGR1
sequences see the following access numbers for IL-2
[NCBI protein: CAA07317] and for IFNGR1 [NCBI pro-
tein: CAI21593]. The reported sequences in the PubMed
databases include the amino acids sequences correspond-
ing to signal peptide at the beginning of the sequences. It
must be taken in account that, the cloned by us sequences
correspond to the mature protein without signal peptide.
TH1 chimeric antagonist biological activities
IL-2 antagonist/agonistic action
The biological activity of the TH1 antagonist protein was
tested in vitro in an assay examining the capacity of the
molecule to inhibit the proliferation of T cells in response
to rhu IL-2. The descriptive statistic indicates that chimeric
protein reduced the activity of IL-2 corresponding to 27.7
IU/mL (median: 28.2, minimum: 20.0, maximum: 34.8
and std. dev 7.6), to 7.5 IU/mL (median 7.9, minimum:
4.2, maximum: 10.0 and std. dev. 2.5), a difference statis-
tically significant with a p = 0.02 (Figure 5 and 6A). The
chimera shares also IL-2 agonistic action, as it sustained
the growth of murine T cells dependent on exogenous IL-
2 (Figure 6A, 6B). In this case, the absorbance measured
during the proliferative assay for CTLL-2 cells incubated
with 2.8 ng/mL of IL-2 has a mean value of 1.6, while for
1.5 µg/mL of TH1 antagonist molecule the absorbance
was approximately the half (Figure 6B).
As mentioned before, the high-affinity receptor for IL-2 is
composed of three subunits, IL-2Rα, IL-2Rβ and IL-2Rγ.
Moreover, the N-terminal IL-2 region contains all the ami-
Electrophoretic mobility of recombinant chimeric protein in reduced and non-reduced conditions Figure 4
Electrophoretic mobility of recombinant chimeric protein in reduced and non-reduced conditions. Panel A: The 
antagonist was identified in a Western blot using a rabbit anti-IL-2 polyclonal antibody. The analyzed TH1 antagonist prepara-
tions were those obtained from the 8 M urea extraction, (lanes a and b), gel filtration fraction in 4 M urea (lanes c and d) and 
after dialysis against PBS (lanes e and f). Panel B: Western blot to identify the TH1 antagonist after dialysis against PBS (lane g) 
and IL-2 (lane h) in reduced conditions using the anti-IL-2 antibody.
2-mercaptoethanol
+     - +     - +      - +        + MW 
kDa
210
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84
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noacids interacting with the IL-2Rα subunit (Lys 35, Arg
38, Phe 42, and Lys 43) and those contacting the IL-2Rβ
subunit (Asp 20 and others) [33]. Then the antagonism
for the biological activity of IL-2 could be explained by the
interaction of IL-2 regions in the fragment of the antago-
nist described as contacting with the indicated IL-2 recep-
tor subunits. Probably the first sixty aminoacid of N-
terminal region of IL-2 can interfere with high-affinity
binding of completely mature IL-2 molecule to its mem-
brane receptor. Otherwise, in the absence of IL-2, the 60-
aminoacid N-terminal IL-2 fragment from TH1 antagonist
chimera might exert the IL-2 agonistic activity. It has been
reported that the N-terminal aminoacid stretch (1–30)
from IL-2 binds to IL-2Rβ and reproduce some of the IL-2
biological functions, as lymphokine activated killer (LAK)
cells activation, induction of IFN-γ production and T cell
proliferation stimulation [34,35]. More work is needed to
precisely demonstrate its dual effects.
TH1 anatagonist neutralization of IFN-γ activities
In order to test for inhibition of antiproliferative action of
rhu IFN-γ we used HEp-2 cells, known to be highly suscep-
tible to growth inhibition by IFN-γ. During antiprolifera-
tive activity assays 2, 4 and 8 ng/ml of IFN-γ inhibited the
growth of HEp-2 cells by approximately 60%. Addition of
50 µg/mL of TH1 antagonist to 2 or 4 IU/mL of IFN-γ fully
restored proliferation of cells. Neutralization of 8 IU/mL
(Figure 7A) was incomplete. The data demonstrated that
the antagonist has the capacity to inhibit the antiprolifer-
ative action of IFN-γ. However, this effect is obtained at a
low molar ratio. This may be due to the high sensitivity of
the HEp-2 cell line to growth inhibition of IFN-γ, as evi-
denced by the data of figure 7, showing that 2 IU/mL of
IFN-γ alone had almost a saturating antiproliferative effect
on HEp-2 cells.
Treatment of Colo 205 with IFN-γ resulted in the induc-
tion of a HLA-DR, a class II MHC antigen, one of the prop-
erties of IFN-γ that account for its immunomodulatory
action. The stimulation of HLA-DR expression by IFN-γ
(0.5 µg/mL) was significantly regulated down (*p = 0.03)
in the presence of the TH1 antagonist (1.5 µg/mL) (Figure
7B). Thus, in the experiments designed to test the in vitro
biological activities of recombinant TH1 antagonist, the
molecule inhibited the antiproliferative and immu-
nomodulatory activities of IFN-γ and the proliferate activ-
ity of IL-2. Based on these in vitro biological activities, the
antagonist demonstrated a high potential to interfere with
the in vivo IL-2 and IFN-γ functions during the activation
of the immune system, a characteristic of the inflamma-
tory and autoimmune conditions. Nonetheless, in vivo
immune response is essentially normal in mice lacking IL-
2 signaling [22]; therefore, the antagonist may not
strongly impact TH1 response in regard to IL-2 during
early in immune response. However, the antagonist may
influence later in the immune response because; IL-2 con-
tributes to T-cell immunity in vivo and seems to be more
important during the later stages of immune responses. It
Inhibition of growth stimulating activity of rhu IL-2 on the mouse cell line CTTL-2 by recombinant chimeric protein Figure 5
Inhibition of growth stimulating activity of rhu IL-2 on the mouse cell line CTTL-2 by recombinant chimeric 
protein. The data are results from 3 independent experiments. The observed difference proved to be statistically different (p 
< 0.05) by the Kruskal-Wallis test. IL-2 dilution 1:40 000 correspond to 25 IU/mL (2.8 ng/mL). Group1: IL-2, group 2: IL-2 + 
TH1 antagonist. Results expressed in international units of IL-2 where 1 IU is defined as the amount of IL-2 that elicits a 50% 
increase in cell growth in a cell base bioassay.
IL-2 IU/mL
40
35
30
25
20
15
10
IL-2                    IL-2 + AnTH1
± ± ± ± Std. Dev             ± ± ± ± Std.Err MeanBMC Biotechnology 2006, 6:25 http://www.biomedcentral.com/1472-6750/6/25
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has been shown to contribute to the type or magnitude of
effectors cells that are produced and to be involved in its
migration or proliferation in non-lymphoid tissue.
The TH1 antagonist has other potentially useful character-
istics. Beside its capacity of interferes with IL-2, it shows
IL-2 agonistic activity, a property that during clinical
application might allow to avoid deactivation of the
immune system, an adverse effect that is characteristic of
current anti-cytokine antagonists therapies, and favors the
occurrence of opportunistic infections, demyelization and
congestive heart failure [36,37]. Furthermore, because IL-
2αR subunit is expressed only in activated T cells, the
antagonist might be targeted mainly to this T cell subset or
to cells expressing the IL-2βR subunit. Thereby, the agent
might be concentrated in the extracellular milieu where
activated T cells are abundant.
The agonistic function of the chimera may also offer the
opportunity to promote the IL-2 dependent regulatory
function of CD4 (+) CD25 (+) T cells, which has been
described as critical in the control of autoimmune dis-
eases[22], in the absence of endogenous IL-2 and likely
interfere with it in the presence of high endogenous IL-2
levels. Nonetheless, the suppressive efficacy of Tr cells iso-
lated from mice subjected to various treatments correlated
closely with suppression of IFN-γ and IL-2 production by
the CD25-effector T cells [38]. In vivo confirmation of
these potential properties of TH1 antagonist will offer
new opportunities to treat several disease conditions
accessible with this therapeutic approach.
Conclusion
We were able to construct and purified a recombinant chi-
meric antagonist composed by a 60 amino acid fragment
of the N-terminal region of human IL-2 fused to the N-ter-
minal of the extracellular region of the alpha subunit of
the gamma IFN-γ receptor was obtained. The chimeric
protein conserves the physicochemical abilities of their
components. This means, the IFN-γ receptor tail is able to
recognize the IFN-γ and in correspondence neutralizes
two biological activities of IFN-γ, its antiproliferative
action on HEp-2 cell line, and the stimulation of HLA-DR
in Colo 205 cells. These data evidenced that the construc-
tion is compatible with the active conformation of the
IFNGR1 extracelluar region. Others experiments con-
firmed that the IL-2 fragment of 60 aminoacids from the
IL-2 N-terminal is in a correct conformation because elicit
a classical well recognized property of IL-2, the stimula-
tion of growth of CTTL-2 cell line dependent on IL-2 for
growth and survival. The data evidenced and demon-
strated that the components are functional in term of their
structure as evidenced from the biological activities they
have.
IL-2 antagonistic/agonistic biological activities of the recombinant chimeric protein Figure 6
IL-2 antagonistic/agonistic biological activities of the recombinant chimeric protein. Panel A: Antagonistic/ago-
nistic biological activities. The figure shows plots of a representative CTLL-2 proliferative assay showing the OD of tested 
samples in each of the evaluated serial dilutions. The IL-2 used for the experiments is the IL-2 international standard (ST-IL-
22010397, 880 000 UI/mL). The arrow shows the OD of IL-2 dilution to test in the presence of serial dilutions of recombinant 
protein. Panel B: Stimulation of T cells proliferation by TH1 antagonist. Bar 1: 2.8 ng/ml of IL-2 (dilution 1:40000), bar 2: 1.5 µg/
ml of AnTH1, bar 3: culture medium without IL-2.
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Methods
Cells
Raji (human Burkitt lymphoma, ATCC: CCL-86) and Jur-
kat (human acute T-cell leukemia, ATCC: TIB-152) cells
were grown in RPMI 1640 supplemented with 10% fetal
calf serum (FCS, Gibco BRL, LIFE TECNOLOGIES™) in
plastic flasks with gentle agitation at 37°C and 5% CO2,
as source of poly-A mRNA. Murine T-cells CTLL-2 (cyto-
toxic T cell, ATCC: TIB-214), human HEp-2 (laryngeal car-
cinoma, ATCC: CCL23) and Colo 205 (human colorectal
adenocarcinoma, ATCC: CLL-222) cell lines were used to
evaluate the biological activity of the antagonist. Cells
were cultured in RPMI 1640 (CTLL-2, Colo 205) and
MEMCANE (HEp-2) containing gentamycin (50 µg/mL)
and 10% FCS at 37°C in a humidified 5% CO2 environ-
ment. E. coli cells W3110 P3 were used for pHu (AnTH1)
plasmid expression.
Isolation of cDNA coding for IL-2 N-terminal and IFNGR1 
extracellular region
Poly-A mRNA purified from 2 × 108 Jurkat and Raji cells,
respectively, using the MessageMaker® mRNA Isolation
System (Invitrogen Life Technologies) was employed for
cDNA RT-PCR amplification. 1–2 µg poly-A mRNAs were
reverse transcribed with GeneAmp RNA PCR kit (Perkin
Elmer Cetus, Norwalk, Conn.) using random hexamers.
The specific primer pairs were the following (overlapping
nucleotides are underlined):
5'CCATGACCTACTTTCAAGTTCTACAAAG3' and
5'CATCATATGGGTCTAGACACTGAAGATGTTTC3' for
the amplification of IL-2 N-terminal, and
5'CCCATATGATGAGCAGGGCTGAGATGGGC3' and
5'GATCCTTATTTTATACTGCTATTGAAAATG3' for the
IFNGR1 extracellular region. Primers for the second
round PCR were: 5'CCATGGCACC
TACTTTCAAGTTCTACAAAG3' and 5'GGATCCTTATTT-
TATACTGC TATTGAAAATG 3'.
Neutralization of biological activities of rhu IFN-γ by recombinant chimeric protein Figure 7
Neutralization of biological activities of rhu IFN-γ by recombinant chimeric protein. Panel A: Inhibition of antipro-
liferative activity of IFN-γ. The inhibition of antiproliferative action of 4 IU/ml of IFN-γ by 50 µg/ml AnTH1 proved to be statis-
tically different (p < 0.05) by the Kruskal-Wallis test. The data are results from 3 independent experiments. The dilutions 
tested for the antagonist were: 1 (1:4), 2 (1:8), 3 (1:16), 4 (1:32), and 5 (1:64). The OD 580 nm of cells without IFN-γ at the begin-
ning of the experiment was 0.139 and after 72 hours on culture was 1.068. Panel B: Inhibition of the IFN-γ induced HLA-DR by 
the AnTh1. The inhibition of IFN-γ (500 IU/mL) HLA-DR stimulation by 1.5 µg/ml AnTh1 proved to be statistically different (p 
< 0.05) by the Kruskal-Wallis test. The data are the results from 3 independent experiments. The amount of IFN-γ was 
denoted as IU of antiviral activity, where 1 IU is defined as the inverse of the dilution that conferred 50% protection to the 
monolayer of cells infected with a virus.
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In brief, first-strand DNA was synthesized in a final vol-
ume of 20 µL from 1 µg poly-A mRNA in DEPC-H2O
using 5 mM MgCL2, 1 mM dNTP, 1 U/µL Rnase inhibitor,
2.5 U/µL MuLV reverse transcriptase, 2.5 µM random hex-
amers, 0.75 µM primers, and 1X PCR buffer II. The mix-
ture was incubated in a DNA Thermal Cycler (MJ
Research, Inn.) at 25°C for 10 minutes, then 1 hour at
42°C followed by 5 minutes at 99°C and then frozen
until use. Complementary DNA (10 µl) were mixed as rec-
ommended by providers with the appropriately specific
primers and reagents (2 mM MgCl2, 2.5 U/100 µL Ampli-
Taq DNA polymerase, 0.15 mM specific primers and 1X
PCR Buffer II). Amplification started with 5 minutes dena-
turation at 94°C, followed by 30 PCR cycles. Each cycle
consisted of 60 seconds at 94°C for denaturation, 40 sec-
onds for annealing (temperature depended on the prim-
ers were used), and 40 seconds at 72°C for extension.
Final extension lasted 5 minutes at 72°C. Twenty five per-
cent of the RT-PCR reaction (5 µl) was transferred to a sec-
ond round reaction mix with the second round primers
and reagents in the same concentrations as described for
PCR. The second round PCR (25 cycles) was done using
the same cycle schedule.
Construction of the TH1 antagonist expression vector
The pTPV-1 plasmid, supplied by the Biomedical Research
Division at CIGB, was employed as expression vector. It
carries the E. coli tryptophan promoter, the bacteriophage
T4 terminator and the ampicillin resistance gene. PTPV-1
vector was digested stepwise with the NcoI and BamHI
enzymes. Second PCR amplified cDNA was digested with
the  BamHI enzyme and processed to eliminate the
enzyme and the buffer. Then PCR product was digested
with NcoI, and processed as described before. Finally, the
vector and the amplified gene fragment were ligated using
the T4 ligase enzyme.
Sequencing of the pHu (AnTH1) plasmid
The sequencing of pHu (AnTH1) plasmid was done using
the  Taq  Dye Deoxy terminator cycle sequencing kit
(Applied Biosystems). One µg of pHu (AnTH1) plasmid
was used as template and annealed with 10 ng forward or
reverse primers, which hybridize with a promoter region
of expression vector. After the separation of unincorpo-
rated dye terminators and primers, the products were
dried in SpeedVac centrifuge, resuspended in loading
buffer, heat denatured and immediately loaded on acryla-
mide gel in an automated DNA sequencer.
Expression of the recombinant protein
E. coli cells, strain W3110P3, containing pHu (AnTH1)
plasmid were grown at 37°C in LB medium with 50 µg/
mL tryptophan and 100 µg/mL ampicillin until the cells
reached an optical density (OD) of 2.0 at 620 nm. Then
cells were inoculated in M9 medium with 4% glucose
without tryptophan and 50 µg/mL ampicillin to a final
OD of 0.25 and grown during 8 hours at 37°C with agita-
tion. Cells were harvested and kept frozen (-20°C) for
future processing.
Extraction of E. coli cells and refolding
To suspend the cells, 10 mL of 10 mM Tris buffer pH 7.2,
1 mM EDTA was added per g of E. coli cells. The cells were
digested with lysozyme and the pellet from the digestion
was washed in a Polytron homogenizer (IKA, Germany)
in 50 mM Tris pH 7.2, 1 mM EDTA containing increasing
urea concentrations (from 1 to 8 mol/L). Cell suspensions
were centrifuged at 12000 rpm at 4°C, 5 min. and super-
natants discarded. The pellet from 4 M urea wash was
finally extracted in a Polytron homogenizer with 10 mM
Tris buffer pH 7.2, 1 mM EDTA containing 8 mol/L urea
(extraction buffer). Cell homogenate was centrifuged at
12000 rpm 5 min. 4°C and supernatant decanted and
stored at -20°C until refolding. Supernatant from the 8 M
urea extraction (150 mL) was loaded on a Sephadex G-
100 column (K9/60 (Pharmacia, Uppsala), equilibrated
with 50 mM Tris HCL pH 7.4 containing 4 M urea. The
elution was performed in the same buffer at 3 mL/minute.
Eluted fractions containing the recombinant protein were
pooled and dialyzed against a buffer containing 0.1 Tris-
HCl, pH 9.0. The dialysis was then continued against
phosphate buffered saline (PBS), pH 7.4.
Ligand-bloting, SDS-PAGE, immuno-blot
For ligand blot, 5-µL fractions from gel filtration chroma-
tography containing folded AnTH1 recombinant protein,
were directly applied to nitrocellulose strips and incu-
bated with 10% defatted milk during 2 h at room temper-
ature. After washing with PBS containing 0.05% Tween 20
(PBS-T), the strips were incubated with 125-I labed recom-
binant IFN-γ, without or in the presence unlabed recom-
binant IFN-γ. Finally, the strips were thrice washed with
PBS-T and exposed for autoradiography. For SDS-PAGE
the samples were loaded in sample buffer with or without
reducing agents. Bands were visualized by Coomassie
Blue R-250 (Sigma) staining.
For immunoblotting samples were loaded as for SDS-
PAGE. After blotting, nitrocellulose strips were incubated
with 10% defatted milk during 2 h at room temperature,
washed (as for ligand blot) and incubated with mouse
anti-IFNGR1 monoclonal antibody R99 (9 µg/mL) or rab-
bit polyclonal antibody against human IL-2 protein,
washed, incubated with anti-mouse or anti-rabbit (IgG)-
peroxidase conjugate in 1% defatted milk and finally
washed. Then, the strips were incubated with developing
solution (H2O2, 5 mg/mL, o-phenylendiamine, and
15%).BMC Biotechnology 2006, 6:25 http://www.biomedcentral.com/1472-6750/6/25
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Aminoacid sequence. In-gel digestion
An aliquot (0.5 µg) of purified protein was analyzed by
SDS-PAGE and reversed-stained with Zn-imidazol [39].
The band was excised and incubated with a 1% citric acid
solution during 5 minutes until complete destaining and
incubated another 10 minutes in water to remove the
excess of chelating agent. The transparent band was addi-
tionally cut in approximately one mm3 cubes dehydrated
in a 90 % acetonitrile aqueous solution without TFA, and
completely dried in a SpeedVac centrifuge. The gels pieces
were rehydrated in 20 µL of 50 mM NH4HCO3 solution
containing 12.5 ng of trypsin, sequencing grade
(Promega, USA). The in-gel digestion was incubated over-
night at 37°C in a thermomixer (Eppendorf, USA). Addi-
tionally, 20 µL of 50 mM NH4HCO3 solution were added
and incubated further for 45 min. Tryptic peptides were
extracted using ZipTips C18 (Millipore, USA) previously
activated and equilibrated as recommended by the manu-
facturer. Twenty loading cycles were carried out for
extracting tryptic peptides. The digest was acidified with
formic acid, incubated 45 minutes at room temperature
and another twenty loading cycles were achieved. The Zip-
tips were washed extensively using a 5 % formic acid solu-
tion and proteolytic peptides eluted in 2 µL of 60 %
acetonitrile containing 1 % formic acid.
Mass spectrometry
The Electrospray ionization (ESI-MS) mass spectra were
acquired using a hybrid quadrupole orthogonal accelera-
tion tandem mass spectrometer QTOF from Micromass
(Manchester, UK) fitted with a Z-spray nanoflow electro-
spray ion source. The mass spectrometer was operated
with a source at 80°C and a drying gas flow of 50 L/h. Two
µL of the tryptic peptides were loaded onto the borosili-
cate nanoflow tip and 900 V and 35 V potentials were
applied to nanoflow tip and entrance cone, respectively.
To obtain information on peptide sequence, the ESI-MS/
MS spectra were acquired as described previously [40].
Data acquisition and processing were performed using the
MassLynx system (v 3.5) from Micromass. The most
intense signals observed in the ESI-MS spectra were
sequenced by MS/MS, sequence tags were manually
extracted and used to identify the proteins by Peptide
Search program [41]. Peptide mass tolerance was 2 Da in
order to identify peptides containing deamidated asparag-
ines residues.
Inhibition of recombinant rhu IL-2 biological activity
The biological activity of rhu IL-2 was assessed as
described [42] using IL-2-dependent murine T lym-
phocyte cell line CTLL-2 [43]. Cells were grown in RPMI-
1640 medium containing 1 mM pyruvate, 2 mM L-
glutamine, 40 mM HEPES, 100 U/mL penicillin, 50 µg/
mL streptomycin, 50 µM 2- mercaptoethanol and 10%
FCS supplemented with 8 U/mL rhu IL-2 (Heber Biotec,
Havana; 1.2 × 107 IU/mg). Before use, cells were washed
thrice, resuspended in complete culture medium without
IL-2 and incubated during 1 h at 37°C in a humidified 5%
CO2 atmosphere. Cells were suspended at a density of 4 ×
105  cells/mL, and distributed into 96-well microtiter
plates (100 µL per well) already containing 100 µL of two-
fold serial dilutions of rhu IL-2 or samples, in complete
medium. Samples consisted of a constant amount of rhu
IL-2 containing serial dilutions of the antagonist. Follow-
ing 36 h of incubation at 37°C, 20 µL of 5 mg/mL of MTT
were added and plates incubated for 4 h in the same envi-
ronment. Finally, 50 µL of 10% SDS/0.1 N HCl/50% iso-
propylalcohol solution were added per well, the plates
agitated for 1 h at 37°C, and the absorbance readed at 570
nm using a microplate reader (Tecnosuma, Havana).
Results were expressed as hu IL-2 units.
Inhibition of rhu IFN-γ antiproliferative action
HEp-2 at 2.5 × 103 cells/mL were seeded in 96-well micro-
titer plates (COSTAR, Cambridge), cultured in MEM-
CANE containing 50 µg/ml gentamycin and 10% FCS, at
37°C in a humidified 5% CO2 environment. Serial dilu-
tions in MEM-CANE medium with 10 % FCS of chimeric
recombinant protein samples were tested. Samples were
mixed with an equal volume of medium containing
appropriated amounts (see figures notes) of rhu IFN-γ
(Heber Biotec, Havana; 1.0 × 107 IU/mg). After adding the
samples, monolayers were incubated during 72 h at 37°C,
5 % CO2. The amount of growing cells in triplicate cul-
tures at each point was determined by Crystal Violet stain-
ing, and absorbance measured at 490 nm using the
microplate reader. The result is defined as % of growth as
follows:
% of growth = (AT72h-AC0h/AC72h-AC0h) × 100.
AT72h = Absorbance from treated culture at 72 hr.
AC72h = Absorbance from control culture at 72 hr.
AC0h = Absorbance from culture just prior to the addition
of IFN.
Inhibition of HLA expression
The biological activity of TH1 antagonist was assessed fur-
ther by testing its ability to prevent IFN-γ from inducing
expression of HLA-DR. A bio-ELISA assay according to the
method of Gibson and colleagues [44] was carried out.
Colo 205 cells were grown to confluence in RPMI 1640
containing 10% FCS, trypsinized and seeded in 96-well
tissue culture plates at a density of 2.5 × 105 cells/well in
0.1 mL of RPMI 1640 containing 10% FCS and finally
incubated for 12 h at 37°C in 5% CO2. Culture media
containing the rhu IFN-γ samples and mixtures of rhu
IFN-γ and antagonist protein were added in a 0.1 mL vol-BMC Biotechnology 2006, 6:25 http://www.biomedcentral.com/1472-6750/6/25
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ume to the wells containing Colo 205 cells, and then incu-
bated for 1 h at 37°C. Following incubation, the media
was removed and wells washed three times with culture
media. Fresh culture media (0.2 ml/well) was added and
plates incubated for 48 h at 37°C to allow for induction
of HLA/DR antigen. Then, the wells were washed with PBS
and fixed for 2 min with ice-cold anhydrous ethyl alcohol.
After the alcohol was removed, the wells were washed
with PBS and incubated for 1 h at room temperature with
mouse monoclonal anti-HLA/DR (DAKO, California)
antibody diluted in PBS containing 0.5% bovine serum
albumin. PBS was used to wash the wells, and peroxidase-
labeled goat anti-mouse IgG was added to each well for 1
h at room temperature. The wells were washed three times
with PBS and then developed as described for the ELISA
plates.
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